Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1996-01-23
1997-05-06
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514 89, 514 90, 514 95, 514100, 514105, 514112, 514114, 544157, 546 22, 549 7, 549220, 556 19, A61K 3166, C07F 938, C07F 940
Patent
active
056271735
ABSTRACT:
Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and prophylaxis of degenerative joint disorders, of rheumatic disorders accompanied by cartilage breakdown, such as rheumatoid arthritis, joint trauma and chondrolysis as a consequence of prolonged immobilization of the joint, of inflammations, septic shock, disorders with impaired leukocyte adhesion, disorders caused by an elevated concentration of tumor necrosis factor alpha, such as cachexia or Crohn's disease.
REFERENCES:
patent: 5137897 (1992-08-01), Thorwart et al.
Cho, Hidetsura et al.; "Novel Caffeic Acid Derivatives: Extremely Potent Inhibitors of 12-Lipoxygenase" Journal of Medicinal Chemistry 34(1991): 1503-1505. 1991.
T. Saeki et al., "Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes From Pig Aorta", Biochemical Pharmacology, 46(5):833-839 (1993).
J. Chenault et al., "Side Reactions in the Phase Transfer Catalysed Wittig-Horner Synthesis. A Convenient Method of Preparation of Hydroxycinnamic Acids", Synthetic Communications, 14(11):1059-1065 (1984).
P. Magnus et al., "Synthesis of the Antileukemic Agent ( )-Steganone Using a Stereoconvergent Biaryl Coupling Reaction", J. Am. Chem. Soc., vol. 107, pp. 4984-4988, 1985.
C. Pollers-Wieers et al., "The Use of Isoquinolinetriones in the Synthesis of Benzo[C]Phenanthridine Alkaloids", Tetrahedron, 37(24-N):4321-4326, 1981.
J. Levine et al., "Intraneuronal Substance P Contributes to the Severity of Experimental Arthritis", Science, 226:547-549 (1984).
D. Burkhardt et al., "Laboratory Evaluation of Glycosaminoglycan Polysulphate Ester for Chondroprotective Activity: A Review", Current Therapeutic Research, 40(6):1034-1053 (1986).
B. Pernow, "Substance P", Pharmacological Reviews, 35(2):85-141 (1983).
K. Kimura et al., "1-4-Di:hydro-pyridine-3-phosphonic acid derivatives", Derwent abstract 84-251757 (1984).
Chem. Ab. 102(15):132271y, "Dihydrohyridyl phosphate derivatives", Nippon Shinyaku Co., Ltd. Jpn., Kokai Tokyo Koho, 41 et seq., 1984.
Bartlett et al., "New 4-hydroxy phenyl-thiazole-2carboxylic acid derivs.--are antiinflammatories, immunomodulators, inhibitors of lipoxygenase, etc. esp. for control of inflammatory rhematic disease", Derwent ab. 008675569 (1991).
Chemical Abstracts, No. 185122e, vol. 114, No. 19, May 13, 1991.
Chemical Abstracts, No. 24234e, vol. 102, No. 3, Jan. 21, 1985.
Chemical Abstracts, No. 55549d, vol. 66, No. 13, Mar. 27, 1967.
Graeve Rolf
M ullner Stefan
Raiss Ruth
Thorwart Werner
Weithmann Klaus U.
Ambrose Michael G.
Hoechst Aktiengesellschaft
Richter Johann
LandOfFree
Phosphonoacetic acid derivatives and their use for treating dege does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphonoacetic acid derivatives and their use for treating dege, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonoacetic acid derivatives and their use for treating dege will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2132789